Doximity (NASDAQ:DOCS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Doximity (NASDAQ:DOCS) had its price objective upped by JPMorgan Chase & Co. from $30.00 to $48.00 in a report published on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

DOCS has been the subject of a number of other research reports. Morgan Stanley raised Doximity from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $33.00 to $53.00 in a research note on Thursday, November 14th. Wells Fargo & Company raised shares of Doximity from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $19.00 to $41.00 in a research note on Friday, November 8th. Needham & Company LLC raised Doximity from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, August 9th. Barclays lifted their price objective on Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, KeyCorp raised Doximity from a “sector weight” rating to an “overweight” rating and set a $70.00 price target for the company in a research note on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $52.27.

Doximity Stock Performance

DOCS stock opened at $48.20 on Thursday. Doximity has a one year low of $22.96 and a one year high of $61.75. The company has a market capitalization of $9.00 billion, a PE ratio of 55.40, a price-to-earnings-growth ratio of 3.89 and a beta of 1.30. The company’s 50 day moving average price is $44.64 and its two-hundred day moving average price is $35.16.

Hedge Funds Weigh In On Doximity

A number of institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC increased its stake in shares of Doximity by 0.6% in the 3rd quarter. MetLife Investment Management LLC now owns 65,064 shares of the company’s stock worth $2,835,000 after purchasing an additional 363 shares in the last quarter. First Horizon Advisors Inc. raised its stake in Doximity by 22.5% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,094 shares of the company’s stock worth $91,000 after acquiring an additional 384 shares during the period. GAMMA Investing LLC lifted its holdings in Doximity by 40.1% during the third quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock valued at $63,000 after purchasing an additional 412 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Doximity by 19.7% during the second quarter. Van ECK Associates Corp now owns 2,590 shares of the company’s stock valued at $72,000 after purchasing an additional 427 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. increased its stake in shares of Doximity by 3.2% in the second quarter. Cornercap Investment Counsel Inc. now owns 17,143 shares of the company’s stock worth $479,000 after purchasing an additional 537 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.